Professional Documents
Culture Documents
Alpha-Glucosidase Inhibitors: Clinically Promising Candidates For Anti-Diabetic Drug Discovery 1st Edition Usman Ghani
Alpha-Glucosidase Inhibitors: Clinically Promising Candidates For Anti-Diabetic Drug Discovery 1st Edition Usman Ghani
https://textbookfull.com/product/drug-discovery-for-
leishmaniasis-1st-edition-luis-rivas/
https://textbookfull.com/product/computational-methods-for-gpcr-
drug-discovery-1st-edition-alexander-heifetz-eds/
https://textbookfull.com/product/drug-discovery-targeting-drug-
resistant-bacteria-1st-edition-prashant-kesharwani-editor/
https://textbookfull.com/product/fragment-based-drug-
discovery-1st-edition-steven-howard/
Heterocyclic chemistry in drug discovery 1st Edition Li
https://textbookfull.com/product/heterocyclic-chemistry-in-drug-
discovery-1st-edition-li/
https://textbookfull.com/product/allosterism-in-drug-discovery-
dario-doller/
https://textbookfull.com/product/successful-drug-discovery-
volume-2-1st-edition-janos-fischer/
https://textbookfull.com/product/antidotes-to-toxins-and-drugs-
from-natural-sources-to-drug-discovery-in-toxicology-drug-
discovery-update-1st-edition-mihnea-alexandru-gaman/
https://textbookfull.com/product/improving-anti-money-laundering-
compliance-self-protecting-theory-and-money-laundering-reporting-
officers-1st-edition-abdullahi-usman-bello-auth/
ALPHA-GLUCOSIDASE
INHIBITORS
ALPHA-GLUCOSIDASE
INHIBITORS
Clinically Promising Candidates
for Antidiabetic Drug Discovery
USMAN GHANI
Associate Professor of Biochemistry,
Clinical Biochemistry Unit, Department of Pathology,
College of Medicine, King Saud University,
Riyadh, Saudi Arabia
Elsevier
Radarweg 29, PO Box 211, 1000 AE Amsterdam, Netherlands
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
Copyright © 2020 Elsevier Ltd. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means,
electronic or mechanical, including photocopying, recording, or any information storage and
retrieval system, without permission in writing from the publisher. Details on how to seek
permission, further information about the Publisher’s permissions policies and our
arrangements with organizations such as the Copyright Clearance Center and the Copyright
Licensing Agency, can be found at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the
Publisher (other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and
experience broaden our understanding, changes in research methods, professional practices, or
medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in
evaluating and using any information, methods, compounds, or experiments described herein.
In using such information or methods they should be mindful of their own safety and the safety
of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors,
assume any liability for any injury and/or damage to persons or property as a matter of products
liability, negligence or otherwise, or from any use or operation of any methods, products,
instructions, or ideas contained in the material herein.
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
ISBN: 978-0-08-102779-0
3. Polyphenols 61
3.1 Chalcones 61
3.2 Xanthones 69
3.3 Flavonoids and other polyphenols 74
References 94
ix
x Contents
xi
Preface
xiii
xiv Preface
Usman Ghani
Acknowledgments
xvii
CHAPTER ONE
Introduction, rationale
and the current clinical status
of oral α-glucosidase inhibitors
Contents
1.1 Introduction 1
1.2 Diabetes mellitus and the antidiabetic drugs 4
1.3 α-Glucosidase inhibitors—past and present 6
1.4 Rationale 10
References 13
1.1 Introduction
Reducing mortality and improving quality of life is one
of the crucial aims of therapeutic agents. Continuing research
in the field of drug discovery has been attracting the attention
of researchers focusing on development of drugs with safer
and better efficacy profiles since these two targets are compul-
sively explored as part of the drug optimization process.
However, need for drugs with safer treatment options and
better efficacy has always been challenging to the drug discov-
ery community, which is generally addressed by alluring temp-
tation of screening the rich and still unexplored molecular
diversity of candidate compounds of natural and synthetic
origins. Despite all these valuable efforts, there exists a down-
turn in the drug screening process. These efforts have been
generating no more than a plethora of active compounds piled
up and forgotten in the ether without being given ample con-
sideration for further development into therapeutic candidacy.
[17] (a) B.L. Nichols, S. Avery, P. Sen, D.M. Swallow, D. Hahn, E. Sterchi,
The maltase-glucoamylase gene: common ancestry to sucrase-
isomaltase with complementary starch digestion activities, Proc.
Natl. Acad. Sci. U.S.A. 100 (2003) 1432 1437.
(b) B.L. Nichols, J. Eldering, S. Avery, D. Hahn, A. Quaroni, E.
Sterchi, Human small intestinal maltase-glucoamylase cDNA clon-
ing. Homology to sucrase-isomaltase, J. Biol. Chem. 273 (1998)
3076 3081.
[18] H.A. Ernst, L. Leggio, M. Willemoës, G. Leonard, P. Blum, S. Larsen,
Structure of the Sulfolobus solfataricus alphaglucosidase: implications for
domain conservation and substrate recognition in GH31, J. Mol. Biol.
358 (2006) 1106 1124.
[19] B. Henrissat, A classification of glycosyl hydrolases based on amino-acid
sequence similarities, Biochem. J. 280 (1991) 309 316.
[20] B. Henrissat, A. Bairoch, New families in the classification of glycosyl
hydrolases based on amino acid sequence similarities, Biochem. J. 293
(1993) 781 788.
[21] A.J. Krentz, C.J. Bailey, Oral antidiabetic agents: current role in type 2
diabetes mellitus, Drugs 65 (2005) 385 411.
[22] D.O. Schmidt, W. Frommer, L. Muller, E. Truscheit, Glucosidase inhi-
bitors from bacilli, Natunlinenschafien 66 (1979) 584 585.
[23] W. Puts, U. Keup, I.J.P. Krause, G. Thomas, F. HoO’meister, Glucosidase
inhibition: a new approach to the treatment of diabetes, obesity and
hyperlipoproteinaemia, Naturwissenschafien 64 (1977) 536 537.
[24] N. Asano, Naturally occurring iminosugars and related compounds:
structure, distribution, and biological activity, Current Topics Med.
Chem. 3 (2003) 471 484.
[25] Y. Kameda, et al., Valiolamine, a new alpha-glucosidase inhibiting ami-
nocyclitol produced by Streptomyces hygroscopicus, J. Antibiot. 37 (1984)
1301 1307.
[26] S. Horii, H. Fukase, T. Matsuo, Y. Kameda, N. Asano, K. Matsui,
Synthesis and α-D-glucosidase inhibitory activity of N-substituted valio-
lamine derivatives as potential oral antidiabetic agents, J. Med. Chem.
29 (1986) 1038 1046.
[27] R. Kawamori, N. Tajima, Y. Iwamoto, A. Kashiwagi, K. Shimamoto,
K. Kaku, Voglibose Ph-3 Study Group. Voglibose for prevention of
type 2 diabetes mellitus: a randomised, doubleblind trial in Japanese indi-
viduals with impaired glucose tolerance, Lancet 373 (2009) 1607 1614.
[28] A. Vichayanrat, S. Ploybutr, M. Tunlakit, P. Watanakejorn, Efficacy
and safety of voglibose in comparison with acarbose in type 2 diabetic
patients, Diabetes Res. Clin. Pract. 55 (2002) 99 103.
[29] S. Inoue, T. Tsuruoka, T. Niida, The structure of nojirimycin, a piperi-
dinose sugar antibiotic, J. Antibiot 19 (1966) 288 292.
Introduction, rationale and the current clinical status of oral α-glucosidase inhibitors 15
FOOTNOTES:
[6] Tcha-tcha, "hurry up" (Zulu).
CHAPTER VII
"IN THE SECOND DOG-WATCH"
All through the tropics, Pedro, under the influence of his solitary
confinement, had been becoming more and more morose and
despondent.
He hardly touched the wretched fare which was placed before him,
and had wasted to a shadow of his former self.
His fierce black eyes glittered out of a sallow, heavily-lined face,
upon which the lowering scowl daily became deeper and deeper.
His ragged moustache was broken and torn by chewing, whilst his
lower lip hung sore and bleeding from the constant gnawing of his
teeth.
"It's a cert," remarked Broncho, "that that bowie-whirlin' dago is due
to go flutterin' from his limb one o' these days. He's lookin' 'bout
ready to break camp for the etarnal beyond; his vittles no longer
gives him joy, an' he just sets thar an' wilts."
"Weevily hard tack and dirty warm water wouldn't give anybody joy,"
replied Jack. "He wants air and exercise; they should let him out for
an hour on deck every day."
"Gate an' seat checks for the realms o' light is about what he wants, I
reckon," retorted the cattle-ranger.
And Broncho was right. One morning they found him too late; he was
lying in a pool of blood with a small piece of broken wood in his
clenched fingers. With this poor weapon the Chilian had managed to
tear open a vein in his arm, and so bled to death. Thus miserably
ended the poor little bucko-killer.
His death brought the superstitious members of the crew to the front
again. Pessimistically they prophesied all sorts of evils, and Sam, the
chief authority, openly proclaimed that Black Davis, with the death of
the ship's cat upon his soul, would be the next victim of the ghostly
avenger.
In the south-east trades easy times reigned in the starboard watch.
For nearly a week not a sheet, brace, or halliard was touched,
except for the usual pull on the braces and general "freshening of
the nip" every evening.
In the second dog-watch the men would collect on the foc's'le head,
and exchange yarns with eager faces and vehement gestures.
Every man forward had seen life in its more unusual phases. Paddy,
Hank, Jack, and the cockney had all been shipwrecked more than
once; and even Jim had had a strange crop of experiences crowded
into his short life.
One evening Jack had just related a yarn of how he had been
wounded in an affray in the New Hebrides, when mate of a
"blackbirder," as the schooners recruiting Kanaka labour for the
Queensland plantations were called.
"Any money in thet layout?" inquired the gambler.
"Used to be," returned Jack, "till the missionaries and opposition in
Australia broke it up."
"Thar's many a cinch in the South Seas," observed Hank. "Copra an'
curios ain't bad, nor yet pearls, speshully if yew kin strike a
preserved patch when thar ain't no gunboat knockin' around."
"Smuggling opium's good, too," reflected Jack musingly.
"Yew bet! Ever tried it?"
"Aye."
"How did it pan out?" inquired Bedrock Ben, somewhat eagerly.
"So-so!" grunted the rover. "Did three good trips. Then we got caught
napping in a typhoon, and the old junk went to the bottom."
"Close call, eh?"
"Yes; only three of us saved—two Chins and myself."